首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Ccl4 |
| Uniprot No | P13236 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-92aa |
| 氨基酸序列 | APMGSDPPTA CCFSYTARKL PRNFVVDYYE TSSLCSQPAV VFQTKRSKQV CADPSESWVQ EYVYDLELN |
| 预测分子量 | 7.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCL4重组蛋白的3篇代表性文献示例(注：内容为模拟概括，非真实文献)：
1. **《High-yield production of recombinant CCL4/MIP-1β in Pichia pastoris and its functional characterization》**
- 作者：Lee, J. et al.
- 摘要：研究利用毕赤酵母系统高效表达重组CCL4蛋白，通过亲和层析纯化获得高纯度产物，并证实其通过CCR5受体激活下游信号通路的能力，验证了其趋化T细胞的生物活性。
2. **《Crystal structure of recombinant human CCL4 reveals molecular basis for chemokine receptor binding》**
- 作者：Zhang, Y. & Smith, R.D.
- 摘要：解析重组人CCL4的晶体结构，阐明其与受体CCR8结合的特定结构域，为设计靶向CCL4的炎症疾病治疗药物提供了结构基础。
3. **《Recombinant CCL4 modulates macrophage polarization in chronic inflammation models》**
- 作者：Gupta, A. et al.
- 摘要：通过体外实验和小鼠模型，证明重组CCL4可促进M1型巨噬细胞向炎症部位募集，并增强其吞噬功能，提示其在调控免疫微环境中的潜在应用。
4. **《Optimization of Escherichia coli expression system for cost-effective CCL4 production》**
- 作者：Kim, S. & Park, H.
- 摘要：优化大肠杆菌表达条件(如诱导温度、IPTG浓度)，提高重组CCL4的可溶性表达水平，降低包涵体形成，为大规模工业化生产提供可行方案。
(注：若需真实文献，建议通过PubMed或Google Scholar以“recombinant CCL4 protein”、“CCL4 expression”等关键词检索近年论文。)
CCL4 (C-C motif chemokine ligand 4), also known as macrophage inflammatory protein-1β (MIP-1β), is a small secretory protein belonging to the CC chemokine family. It plays a critical role in regulating immune responses by recruiting and activating leukocytes, particularly monocytes, dendritic cells, and T lymphocytes, through interaction with its cognate receptors CCR5 and CCR3. CCL4 is produced by various cell types, including macrophages, fibroblasts, and endothelial cells, in response to inflammatory stimuli such as cytokines (e.g., TNF-α, IL-1β) or pathogen-associated molecular patterns.
Recombinant CCL4 protein is engineered using genetic modification techniques, often expressed in prokaryotic (e.g., *E. coli*) or eukaryotic systems (e.g., mammalian cells) to ensure proper folding and post-translational modifications. The recombinant form retains the native protein's functional properties, including receptor binding and chemotactic activity, making it a valuable tool for studying inflammatory pathways, immune cell migration, and host-pathogen interactions. It is typically purified via affinity chromatography, with tags like His-tag for ease of isolation.
In research, recombinant CCL4 is widely used to model inflammatory diseases, HIV pathogenesis (as CCR5 is a co-receptor for viral entry), and cancer metastasis. It also serves as a reference standard in drug discovery targeting chemokine receptors. Recent studies explore its dual role in both promoting and suppressing tumor growth, highlighting context-dependent functions. Quality control assays, such as SDS-PAGE and bioactivity tests, ensure batch consistency for experimental reproducibility.
×
